Immunotherapy combo shows promise against early lung cancer in small trial
NCT ID NCT05775796
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the drug serplulimab (an immunotherapy) combined with standard chemotherapy in 30 people with stage II-IIIA non-small cell lung cancer that could be surgically removed. The treatment was given before and after surgery to see if it could shrink tumors and improve outcomes. The study is complete, and results will help determine if this combination is safe and effective enough for larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Serplulimab combined with chemotherapy (paclitaxel or pemetrexed plus cisplatin or carboplatin)
- What this could lead to
- If successful, this could point toward a more effective treatment approach for early-stage lung cancer, potentially improving surgical outcomes and reducing recurrence.
- What could go wrong
- This is a small, early-phase trial with only 30 participants and no comparison group, so results may not be conclusive. The combination therapy also carries risks of side effects from both immunotherapy and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?